Streetbeat News

Analyst Ratings

FDX

FedEx is set to release its Q1 earnings, with expectations of $4.83 EPS and $21.99 billion in revenue. Despite a lawsuit from the EEOC, FedEx shares rose 1.6%. Analysts have adjusted price targets, mostly maintaining positive ratings.

Portfolio Pulse from Avi Kapoor

September 18, 2024 | 5:55 pm

CFLT

DA Davidson analyst Rudy Kessinger maintains a Buy rating on Confluent (NASDAQ:CFLT) with a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:54 pm

PYPL

Keefe, Bruyette & Woods has reiterated its 'Outperform' rating for PayPal Holdings, maintaining a price target of $78.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:52 pm

ELF

DA Davidson analyst Linda Bolton Weiser maintains a Buy rating on e.l.f. Beauty with a price target of $223.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:50 pm

IPAR

DA Davidson analyst Linda Bolton Weiser has reiterated a Buy rating for Inter Parfums (NASDAQ:IPAR) with a maintained price target of $163.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:48 pm

BRCC

DA Davidson analyst Michael Baker maintains a Buy rating on BRC (NYSE:BRCC) with a price target of $5.5.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:45 pm

ORIC

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating for ORIC Pharmaceuticals, maintaining a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:33 pm

MRK

Deep-pocketed investors are showing a bullish trend towards Merck & Co (NYSE:MRK) through significant options activities. Benzinga's options scanner detected 8 extraordinary options trades, with 75% of the sentiment being bullish. The targeted price range for MRK is between $100 and $145. The stock is currently trading at $118.3, with a slight increase of 0.01%. Analysts have set an average target price of $155.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 5:32 pm

GME

GameStop (NYSE:GME) is experiencing significant options trading activity, with a majority of trades being bearish. This suggests that large investors anticipate potential price movements. The current price is $19.55, down 3.03%, with a neutral RSI. Analysts have a target price of $10.0.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 5:32 pm

ANIP

Raymond James analyst Elliot Wilbur has maintained an Outperform rating on ANI Pharmaceuticals and raised the price target from $81 to $83.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 5:31 pm